These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
193 related items for PubMed ID: 12349828
1. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG. Mol Ther; 2002 Aug; 6(2):287-97. PubMed ID: 12349828 [Abstract] [Full Text] [Related]
2. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. Harvey BG, Hackett NR, El-Sawy T, Rosengart TK, Hirschowitz EA, Lieberman MD, Lesser ML, Crystal RG. J Virol; 1999 Aug; 73(8):6729-42. PubMed ID: 10400771 [Abstract] [Full Text] [Related]
3. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG. Hum Gene Ther; 2002 Jan 01; 13(1):15-63. PubMed ID: 11779412 [Abstract] [Full Text] [Related]
4. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C. Hum Gene Ther; 2002 Jan 01; 13(1):65-100. PubMed ID: 11779413 [Abstract] [Full Text] [Related]
5. Host responses and persistence of vector genome following intrabronchial administration of an E1(-)E3(-) adenovirus gene transfer vector to normal individuals. Harvey BG, Hackett NR, Ely S, Crystal RG. Mol Ther; 2001 Feb 01; 3(2):206-15. PubMed ID: 11237677 [Abstract] [Full Text] [Related]
6. Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo. Hackett NR, El Sawy T, Lee LY, Silva I, O'Leary J, Rosengart TK, Crystal RG. Mol Ther; 2000 Dec 01; 2(6):649-56. PubMed ID: 11124067 [Abstract] [Full Text] [Related]
7. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Joseph PM, O'Sullivan BP, Lapey A, Dorkin H, Oren J, Balfour R, Perricone MA, Rosenberg M, Wadsworth SC, Smith AE, St George JA, Meeker DP. Hum Gene Ther; 2001 Jul 20; 12(11):1369-82. PubMed ID: 11485629 [Abstract] [Full Text] [Related]
8. Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121. Patel SR, Lee LY, Mack CA, Polce DR, El-Sawy T, Hackett NR, Ilercil A, Jones EC, Hahn RT, Isom OW, Rosengart TK, Crystal RG. Hum Gene Ther; 1999 May 20; 10(8):1331-48. PubMed ID: 10365664 [Abstract] [Full Text] [Related]
9. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG. Circulation; 1999 Aug 03; 100(5):468-74. PubMed ID: 10430759 [Abstract] [Full Text] [Related]
12. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL, Kaner RJ, Ferris B, Gonda I, Sweeney TD, Ramalingam R, Kovesdi I, Shak S, Crystal RG. J Clin Invest; 1999 Nov 03; 104(9):1245-55. PubMed ID: 10545523 [Abstract] [Full Text] [Related]
13. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector. Harvey BG, Worgall S, Ely S, Leopold PL, Crystal RG. Hum Gene Ther; 1999 Nov 20; 10(17):2823-37. PubMed ID: 10584928 [Abstract] [Full Text] [Related]
14. Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Topf N, Worgall S, Hackett NR, Crystal RG. Gene Ther; 1998 Apr 20; 5(4):507-13. PubMed ID: 9614575 [Abstract] [Full Text] [Related]
15. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG. Ann Surg; 1999 Oct 20; 230(4):466-70; discussion 470-2. PubMed ID: 10522716 [Abstract] [Full Text] [Related]
16. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT, Danel C. Nat Genet; 1994 Sep 20; 8(1):42-51. PubMed ID: 7527271 [Abstract] [Full Text] [Related]
17. [Aerosol administration of a replication defective recombinant adenovirus expressing normal human cDNA-CFTR in the respiratory tractus in patients with cystic fibrosis]. Bellon G, Calmard L, Thouvenot D, Levrey H, Jagneaux V, Poitevin F, Malcus C, Accart N, Séné C, Layani MP, Aymard M, Bienvenu J, Courtney M, Döring G, Gilly B, Gilly R, Lamy D, Morel Y, Paulin C, Perraud F, Rodillon L, So S, Touraine F, Schatz C, Pavirani A. C R Seances Soc Biol Fil; 1996 Sep 20; 190(1):109-42. PubMed ID: 8881273 [Abstract] [Full Text] [Related]
18. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Mastrangeli A, Harvey BG, Yao J, Wolff G, Kovesdi I, Crystal RG, Falck-Pedersen E. Hum Gene Ther; 1996 Jan 20; 7(1):79-87. PubMed ID: 8825871 [Abstract] [Full Text] [Related]
19. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C, Yankelevitz D, Kemeny N, Silverstein R, Ohwada A, Russi T, Mastrangeli A, Sanders A, Cooke J, Harvey BG. Hum Gene Ther; 1997 May 20; 8(8):985-1001. PubMed ID: 9195221 [No Abstract] [Full Text] [Related]
20. VEGF gene therapy for coronary artery disease and peripheral vascular disease. Rasmussen HS, Rasmussen CS, Macko J. Cardiovasc Radiat Med; 2002 May 20; 3(2):114-7. PubMed ID: 12699842 [Abstract] [Full Text] [Related] Page: [Next] [New Search]